Key clinical point: Eltrombopag showed good safety and promising clinical activity in patients with immune thrombocytopenia (ITP) secondary to chronic lymphoproliferative disorders.
Major finding: At 4 weeks, the platelet response rate was 78%, with a complete response rate of 50%.
Study details: An open-label phase 2 study of 18 patients with ITP secondary to chronic lymphoproliferative disorders.
Disclosures: The study was funded by the Hematology Project Foundation, Vicenza. The authors reported financial affiliations with Amgen, Argenx, and Novartis.
Visco C et al. Blood. 2019 Sep 30. doi: 10.1182/blood.2019001617.